BlackBerry Limited vs Regeneron Pharmaceuticals Inc — how do they compare? BlackBerry Limited trades at $11.06 (market cap $6.26B), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.1× BlackBerry Limited's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while BlackBerry Limited pays none. Which is the better fit depends on your goals.
| BB | REGN | |
|---|---|---|
Market Cap | $6.26B | $69.52B |
Sector | Technology | Health |
52-Week High | $12.81 | $812.27 |
52-Week Low | $3.15 | $542.52 |
Enterprise Value | $6.13B | $63.47B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $10.71, down 2.37% today, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q1 2026 earnings beat expectations with EPS of $0.06 versus $0.05 expected, driven by QNX software growth. Revenue for 2025 was $534.90M with a net loss of $79M, but 2026 projects a return to profitability. Positive news highlights QNX expansion into robotics and industrial automation.
Outlook is cautiously optimistic as the company's turnaround gains traction, but high valuation ratios (P/E 107.1) and mixed analyst sentiment (14% buy, 86% hold) suggest execution risks remain. Key opportunities include QNX's market penetration, while risks involve competitive pressures and achieving sustained profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →